サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1723660

RSVワクチン市場：ワクチンタイプ別、投与経路別、対象患者層別、流通チャネル別、主要地域別、主要企業別：2040年までの業界動向と世界の予測

RSV Vaccine Market by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions, and Leading Players: Industry Trends and Global Forecasts, till 2040

出版日
ページ情報
英文 378 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
RSVワクチン市場：ワクチンタイプ別、投与経路別、対象患者層別、流通チャネル別、主要地域別、主要企業別：2040年までの業界動向と世界の予測
出版日: 2025年05月09日
発行: Roots Analysis
ページ情報: 英文 378 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

RSVワクチン市場

世界のRSVワクチンの市場規模は今年11億4,900万米ドルとなりました。同市場は、2040年には7億3,100万米ドルになると予測されています。

RSVワクチン市場の機会は以下のセグメントに分布しています：

ワクチンタイプ

  • サブユニット/ウイルス様粒子（VLP）ワクチン
  • 生ワクチン
  • mRNAワクチン

投与経路

  • 筋肉内
  • その他

対象患者層

  • 高齢者
  • 乳幼児／小児
  • 妊婦

流通チャネル

  • 薬局・薬店
  • 政府／機関納入業者
  • その他

主な地域

  • 北米
  • 欧州

RSVワクチン市場：成長と動向

呼吸器合胞体ウイルス（RSV）は、乳幼児、高齢者、免疫不全者に下気道感染症を蔓延させる一般的なウイルスです。このウイルスは感染力の強い呼吸器病原体として認識されており、世界中で重篤な疾患や死亡の原因となっています。WHOによると、全世界で5歳未満の小児に毎年約3,300万件のRSV感染症が新たに発生しています。これは、RSV感染症に対する有効な治療法がないことに起因しています。

現在、RSV感染症の治療には、市販薬、点鼻薬、加湿器などいくつかの予防法が用いられています。しかし、これらは対症療法に過ぎないため、安全で効果的な標的治療を患者に提供するワクチンが有望な選択肢となっています。これらのワクチンは、気管支炎や肺炎などの呼吸器疾患だけでなく、RSV感染症に関連する入院率、合併症、死亡率を最小限に抑える可能性を秘めています。

RSV Vaccine Market-IMG1

RSVワクチン開発のためのmRNAやナノ粒子技術の使用など、技術の進歩に後押しされ、これらのワクチンはRSV感染症に対して長期間の免疫と効果的な治療を提供しています。さらに、RSV治療のための研究開発努力と臨床試験件数の増加により、RSVワクチンの需要は増加すると予想され、市場は今後数年間で健全な成長を遂げるものと思われます。

RSVワクチン市場：主要インサイト

本レポートでは、RSVワクチン市場の現状を調査し、業界内の潜在的な成長機会を特定しています。主な調査結果は以下の通り：

  • 現在、70種類以上のRSVワクチンが様々な技術を用いて開発されており、特にこれらのワクチンの60%以上が様々な臨床試験段階で検討されています。
RSV Vaccine Market-IMG2
  • RSVワクチンに対する需要の高まりは、ワクチンパイプラインの顕著な増加をもたらし、現在約65種のワクチンが前臨床および臨床開発段階にあります。
  • RSVワクチンを評価する臨床試験の85％以上は、業界企業がスポンサーとなっています。
RSV Vaccine Market-IMG3
  • 2020年以降、RSVワクチン領域では330件以上の特許が出願／付与されており、特許の大半は北米で出願されています（50％以上）。
  • 呼吸器合胞体ウイルス感染症の流行が拡大していることと、技術進歩のペースが増していることが、RSVワクチン市場を牽引しており、当面は安定した成長が見込まれます。
  • RSVワクチン市場の全体的な機会は、様々な主要地域、ワクチンタイプ、投与経路、対象患者集団、流通チャネルに分散していると予想されます。
RSV Vaccine Market-IMG4

RSVワクチン市場：主要セグメント

ワクチンタイプにより、世界のRSVワクチン市場はサブユニット/ウイルス様粒子（VLP）ワクチン、弱毒化生ワクチンとmRNAワクチンに区分されます。現在、RSVワクチン市場の大半のシェアをサブユニット/ウイルス様粒子（VLP）ワクチンが占めています。これは、これらのワクチンが親ウイルスと形態的に類似しているため、強い免疫原性反応が生じるためです。

世界のRSVワクチン市場は、投与経路によって筋肉内投与とその他の経路に分かれます。現在のところ、筋肉内経路で投与されるワクチンが市場全体を支配する可能性が高いです。これは、効率的な吸収を保証する高いバイオアベイラビリティと、副作用の軽減により、患者にとってより安全で効果的な選択肢となることに起因しています。

世界のRSVワクチン市場は、対象とする患者層によって、高齢者、乳幼児・小児、妊娠中の患者に区分されます。現在のRSVワクチン市場は、高齢者セグメントが支配的であろう。これは、高齢者が呼吸器疾患、特にRSVシーズン中に非常に罹患しやすいことに起因しています。

世界のRSVワクチン市場は、流通チャネル別に薬局・薬店、政府・機関納入業者、その他に区分されます。注目すべきは、薬局・薬店セグメントが予測期間中にRSVワクチン市場を独占する可能性が高いことです。これは、利便性が高く、広く利用しやすいことに加え、ワクチン接種率の上昇に寄与している薬剤師によるワクチン投与の認可が高まっているためです。

主要地域別に見ると、市場は北米と欧州に区分されます。現在のところ、北米が最大の市場シェアを獲得しているが、これは同地域における呼吸器感染症の増加、強固な規制の枠組み、先進的なヘルスケアインフラに起因しています。

本レポートでお答えする主な質問

  • 現在、何社がこの市場に参入しているか
  • この市場の主要企業
  • この市場の進化に影響を与えそうな要因
  • 現在と将来の市場規模
  • この市場のCAGR
  • 現在および将来の市場機会は、主要市場セグメントにどのように分配されそうか
  • 市場における特許出願動向

本レポートを購入する理由

  • 本レポートは包括的な市場分析を提供し、市場全体と特定のサブセグメントに関する詳細な収益予測を提供します。この情報は、すでに市場をリードしている企業にとっても、新規参入企業にとっても貴重なものです。
  • 利害関係者は、市場内の競争力学をより深く理解するためにレポートを活用することができます。競合情勢を分析することで、企業は、市場でのポジショニングを最適化し、効果的な市場参入戦略を開発するために、情報に基づいた意思決定を行うことができます。
  • 当レポートは、主要促進要因・市場抑制要因・課題など、市場の包括的な概要を利害関係者に提供します。この情報は、利害関係者が市場動向を常に把握し、成長の見込みを活用するためのデータ主導の意思決定を行うための力となります。

その他の特典

  • レポート内の全分析モジュールの無料エクセルデータパック
  • 10％の無料コンテンツカスタマイズ
  • 調査チームによる詳細レポートのウォークスルーセッション
  • レポートが6-12ヶ月以上前の場合、無料更新レポート

当レポートでは、世界のRSVワクチン市場について調査し、市場の概要とともに、ワクチンタイプ別、投与経路別、対象患者層別、流通チャネル別、主要地域別、主要企業別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

セクションI：レポートの概要

第1章 背景

第2章 調査手法

第3章 市場力学

第4章 マクロ経済指標

セクションII：定性的な洞察

第5章 エグゼクティブサマリー

第6章 イントロダクション

  • RSウイルスワクチンのイントロダクション
  • RSVの構造とメカニズム
  • RSウイルスワクチンに関連する主要な歴史的出来事
  • RSウイルスワクチンタイプ
  • RSウイルスワクチン接種の利点
  • RSウイルスワクチン開発に伴う課題
  • 将来の展望

セクションIII：市場概要

第7章 市場情勢

  • RSウイルスワクチン：市場情勢

第8章 製品競争力分析

  • 前提と主要なパラメータ
  • 調査手法
  • RSウイルスワクチン：製品競争力分析

セクションIV：企業プロファイル

第9章 企業プロファイル北米のRSウイルスワクチン開発企業

  • Icosavax（A Company of AstraZeneca）
  • Moderna
  • Pfizer

第10章 企業プロファイル：欧州のRSVワクチン開発企業

  • GlaxoSmithKline
  • Sanofi

第11章 企業プロファイル：アジア太平洋のRSVワクチン開発企業

  • Beijing Advaccine Biotechnology

第5章 市場動向

第12章 臨床試験の分析

  • 範囲と調査手法
  • RSウイルスワクチン：臨床試験分析

第13章 特許分析

第14章 FDA承認戦略

セクションVI：市場機会分析

第15章 市場影響分析：促進要因、抑制要因、機会、課題

  • 市場の促進要因
  • 市場の抑制要因
  • 市場の機会
  • 市場の課題

第16章 世界のRSVワクチン市場

第17章 RSウイルスワクチン市場（ワクチンタイプ別）

第18章 RSウイルスワクチン市場（投与経路別）

第19章 RSウイルスワクチン市場（対象患者層別）

第20章 RSウイルスワクチン市場（流通チャネル別）

第21章 RSウイルスワクチン市場（主要地域別）

第22章 市場集中分析（主要参入企業別）

セクションVII：地理的地域における市場機会分析

第23章 市場機会分析：北米

第24章 市場機会分析：欧州

セクションVIII：その他の独占的洞察

第25章 結論

第26章 エグゼクティブ洞察

セクションIX：付録

第27章 表形式データ

第28章 企業・団体一覧

図表

List of Tables

  • Table 7.1 RSV Vaccines: Information on Developer, Stage of Development, Route of Administration and Type of Vaccine
  • Table 7.2 RSV Vaccines: Information on Type of Protein Targeted, Type of Immunization and Target Patient Population
  • Table 7.3 RSV Vaccines: List of Developers
  • Table 9.1 Icosavax (A Company of AstraZeneca): Product Portfolio
  • Table 9.2 Moderna: Product Portfolio
  • Table 9.3 Pfizer: Product Portfolio
  • Table 10.1 GlaxoSmithKline: Product Portfolio
  • Table 10.2 Sanofi: Product Portfolio
  • Table 11.1 Beijing Advaccine Biotechnology: Product Portfolio
  • Table 13.1 RSV Vaccine Market: List of Published Patents
  • Table 23.1 RSV Vaccine Market in North America: Distribution by Type of Vaccine, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 23.2 RSV Vaccine Market in North America: Distribution by Route of Administration, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 23.3 RSV Vaccine Market in North America: Distribution by Target Patient Population, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 23.4 RSV Vaccine Market in North America: Distribution by Distribution Channel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.1 RSV Vaccine Market in Europe: Distribution by Type of Vaccine, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.2 RSV Vaccine Market in Europe: Distribution by Route of Administration, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.3 RSV Vaccine Market in Europe: Distribution by Target Patient Population, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.4 RSV Vaccine Market in Europe: Distribution by Distribution Channel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • *Detailed information on Tables 23.1-24.4 is available in the Excel Data Packs shared along with the report
  • Table 27.1 RSV Vaccines: Distribution by Stage of Development
  • Table 27.2 RSV Vaccines: Distribution by Route of Administration
  • Table 27.3 RSV Vaccines: Distribution by Type of Vaccine
  • Table 27.4 RSV Vaccines: Distribution by Type of Protein Targeted
  • Table 27.5 RSV Vaccines: Distribution by Type of Immunization
  • Table 27.6 RSV Vaccines: Distribution by Target Patient Population
  • Table 27.7 RSV Vaccine Developers: Distribution by Year of Establishment
  • Table 27.8 RSV Vaccine Developers: Distribution by Company Size
  • Table 27.9 RSV Vaccine Developers: Distribution by Location of Headquarters
  • Table 27.10 Moderna: Consolidated Financial Details, FY 2021 onwards (USD Million)
  • Table 27.11 Pfizer: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (USD Million)
  • Table 27.12 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
  • Table 27.13 Sanofi: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
  • Table 27.14 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2015
  • Table 27.15 Clinical Trial Analysis: Distribution by Trial Status
  • Table 27.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Since 2015
  • Table 27.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2015
  • Table 27.18 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 27.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 27.20 Clinical Trial Analysis: Distribution by Study Design
  • Table 27.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 27.22 Clinical Trial Analysis: Distribution by Gender
  • Table 27.23 Clinical Trial Analysis: Distribution by Target Patient Population
  • Table 27.24 Leading Players: Distribution by Number of Registered Trial
  • Table 27.25 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Table 27.26 Clinical Trial Analysis: Distribution by Trial Status and Geography
  • Table 27.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Table 27.28 Patent Analysis: Distribution by Patent Publication Year, Since 2020
  • Table 27.29 Patent Analysis: Distribution by Type of Patent
  • Table 27.30 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
  • Table 27.31 Patent Analysis: Distribution by Patent Application Year, Since 2008
  • Table 27.32 Patent Analysis: Distribution by Patent Age
  • Table 27.33 Cumulative Year-wise Distribution by Type of Applicant
  • Table 27.34 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 27.35 Leading Industry Players: Distribution by Number of Patents
  • Table 27.36 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 27.37 Leading Inventors: Distribution by Number of Patents
  • Table 27.38 RSV Vaccines: Patent Valuation
  • Table 27.39 Global RSV Vaccine Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 27.40 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Conservative Scenario (USD Million)
  • Table 27.41 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Optimistic Scenario (USD Million)
  • Table 27.42 RSV Vaccine Market: Distribution by Type of Vaccine
  • Table 27.43 RSV Vaccine Market for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.44 RSV Vaccine Market for Live Attenuated / Chimeric Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.45 RSV Vaccine Market for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.46 RSV Vaccine Market: Distribution by Route of Administration
  • Table 27.47 RSV Vaccine Market for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.48 RSV Vaccine Market for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.49 RSV Vaccine Market: Distribution by Target Patient Population
  • Table 27.50 RSV Vaccine Market for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.51 RSV Vaccine Market for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.52 RSV Vaccine Market for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.53 RSV Vaccine Market: Distribution by Distribution channel
  • Table 27.54 RSV Vaccine Market for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.55 RSV Vaccine Market for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.56 RSV Vaccine Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.57 RSV Vaccine Market: Distribution by Key Geographical Regions
  • Table 27.58 RSV Vaccine Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.59 RSV Vaccine Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.60 Market Movement Analysis: Key Geographical Regions
  • Table 27.61 Penetration Growth Matrix: Key Geographical Regions
  • Table 27.62 RSV Vaccine Market: Distribution by Leading Players
目次
Product Code: RA100525

RSV VACCINE MARKET

As per Roots Analysis, the global RSV vaccine market size is worth USD 1,149 million in the current year and is expected to be worth USD 731 million by 2040.

The opportunity for RSV vaccine market has been distributed across the following segments:

Type of Vaccine

  • Subunit / Viral-like-Particle (VLP) Vaccines
  • Live Attenuated Vaccines
  • mRNA Vaccines

Route of Administration

  • Intramuscular
  • Other Routes

Target Patient Population

  • Elderly Individuals
  • Infants / Children
  • Pregnant Individuals

Distribution Channel

  • Pharmacies and Drug Stores
  • Government / Institutional Suppliers
  • Others

Key Geographical Regions

  • North America
  • Europe

RSV VACCINE MARKET: GROWTH AND TRENDS

Respiratory Syncytial Virus (RSV) is a common virus spreading lower respiratory tract infections in infants, older adults, and immunocompromised individuals. This virus is recognized as a highly contagious respiratory pathogen, which contributes to severe illness and mortality across the globe. According to the WHO, around 33 million new cases of RSV infections are emerging annually in children under the age of five across the globe. This can be attributed to the lack of effective treatment options for RSV infections.

Currently, several preventive measures, such as over-the-counter medications, nasal sprays, and humidifiers are being used for the treatment of RSV infections. However, they only provide symptomatic relief, making vaccines a promising alternative that offers safe, effective and targeted treatment to patients. These vaccines have the potential to minimize hospitalization rates, complications, and mortality rates related to RSV infections as well as other respiratory illnesses, such as bronchitis and pneumonia.

RSV Vaccine Market - IMG1

Driven by technological advancements, including the use of mRNA and nanoparticle technology for developing RSV vaccines, these vaccines are providing long lasting immunity and effective treatment against RSV infections. Moreover, owing to the increased research and development efforts and rising number of clinical trials for RSV treatment, the demand for RSV vaccines is anticipated to rise, positioning the market for healthy growth in the forthcoming years.

RSV VACCINE MARKET: KEY INSIGHTS

The report delves into the current state of the RSV vaccine market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • Presently, more than 70 RSV vaccines are being developed using various technologies; notably, over 60% of these vaccines are under investigation in different clinical trial phases.
RSV Vaccine Market - IMG2
  • The rising demand for RSV vaccines has led to a notable increase in the vaccine pipeline, with around 65 vaccines currently under preclinical and clinical stages of development.
  • A sizeable increase in the number of registered clinical trials has been observed in recent years; over 85% of the trials evaluating RSV vaccines have been sponsored by industry players.
RSV Vaccine Market - IMG3
  • Since 2020, more than 330 patents have been filed / granted in the RSV vaccines domain; further, the majority of the patents were filed in North America (>50%).
  • The growing prevalence of respiratory syncytial virus infections, coupled with the increasing pace of technological advancements is driving the RSV vaccines market and positioning it for steady growth in the foreseeable future.
  • The overall opportunity within the RSV vaccine market is anticipated to be well distributed across various key geographical regions, types of vaccines, routes of administration, target patient populations and distribution channels.
RSV Vaccine Market - IMG4

RSV VACCINE MARKET: KEY SEGMENTS

Subunit / Viral-Like-Particle (VLP) Vaccines are Likely to Dominate the RSV Vaccine Market During the Forecast Period

Based on the types of vaccines, the global RSV vaccine market is segmented into subunit / viral-like-particle (VLP) vaccines, live attenuated vaccines and mRNA vaccines. Currently, the majority share of the RSV vaccine market is captured by subunit / Viral-Like-Particle (VLP) vaccines, owing to the strong immunogenic response produced by these vaccines since they are morphologically similar to their parent virus.

Vaccines Administered through Intramuscular Route are Likely to Hold the Largest Share of the RSV Vaccine Market during the Forecast Period

Based on the route of administration, the global RSV vaccine market is distributed across intramuscular and other routes. Currently, the vaccines administered through the intramuscular route are likely to dominate the overall market. This can be attributed to their high bioavailability, which ensures efficient absorption, along with reduced side effects, making them a safer and more effective option for patients.

By Target Patient Population, RSV Vaccines Developed for Elderly Individuals are Likely to Dominate the Market during the Forecast Period

Based on the target patient population, the global RSV vaccine market is segmented into elderly individuals, infants / children and pregnant individuals. The current RSV vaccine market is likely to be dominated by elderly individuals' segment. This can be attributed to the fact that elderly individuals are highly susceptible to respiratory diseases, specifically during RSV season.

By Type of Material, Stainless Steel Segment is Likely to Dominate the Market During the Forecast Period

Based on the distribution channel, the global RSV vaccine market is segmented into pharmacies and drug stores, government / institutional suppliers and others. Notably, the pharmacies and drug stores segment are likely to dominate the RSV vaccine market during the forecast period. This can be attributed to their convenience and widespread accessibility, along with the rising authorization of pharmacists to administer vaccines which has contributed to increased vaccination rates.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America and Europe. In the current scenario, North America is likely to capture the largest market share which can be attributed to the growing incidences of respiratory infections, robust regulatory frameworks, and advanced healthcare infrastructure in this region.

Example Players in the RSV Vaccine Market

  • AIM Vaccine
  • Beijing Advaccine Biotechnology
  • CureVac
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Icosavax (A company of AstraZeneca)
  • Johnson & Johnson
  • KM Biologics
  • MedImmune (A part of AstraZeneca)
  • Moderna
  • Pfizer
  • Sanofi
  • SK Bioscience

RSV VACCINE MARKET: RESEARCH COVERAGE

The report on the RSV vaccine market features insights on various sections, including:

  • Market Sizing and Opportunity Analysis: An in-depth analysis of the RSV vaccine market, focusing on key market segments, including [A] type of vaccine, [B] route of administration, [C] target patient population, [D] distribution channel, and [E] key geographical regions and [F] leading players.
  • Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.
  • RSV Vaccines Market Landscape: A comprehensive evaluation of various RSV vaccines, based on several relevant parameters, such as [A] stage of development, [B] route of administration, [C] type of vaccine, [D] type of protein targeted, [E] type of immunization, and [F] target patient population. This section also includes an evaluation of the companies engaged in developing RSV vaccines, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters.
  • Product Competitiveness Analysis: An insightful competitiveness analysis of various RSV vaccines based on various relevant parameters, such as [A] developer strength, [B] product competitiveness, and [C] portfolio diversity.
  • Company Profiles: Elaborate profiles of prominent RSV vaccine developers across various geographies, including North America, Europe, Asia-Pacific, providing details on [A] company overview, [B] financial information (if available), [C] product portfolio, [D] recent developments and [E] an informed future outlook.
  • Clinical Trial Analysis: A detailed assessment of clinical trials that have been published for various types of RSV vaccines, based on various relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] study design, [E] type of sponsor / collaborator, [F] gender, [G] target patient population, [H] leading players and [I] geography.
  • Patent Analysis: An in-depth analysis of patents filed / granted till date in the RSV vaccine domain, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] patent application year, [D] CPC symbols, [E] patent jurisdiction, [F] type of applicant, [G] leading industry players, [H] leading industry players, [I] patent benchmarking, [J] patent age, and [K] patent valuation analysis.
  • FDA Approval Strategies: A detailed overview of various competitive strategies that can be incorporated by the RSV vaccine developers in order to expedite the FDA approval process of their proprietary vaccines. The section also provides information on several stakeholders undertaking various initiatives, including awards / grants, partnerships, and expanding intellectual properties.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What is the patent filing activity trend in the market?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

SECTION I: REPORT OVERVIEW

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Introduction to RSV Vaccines
  • 6.2. Structure and Mechanism of RSV
  • 6.3. Key Historical Events Related to RSV Vaccines
  • 6.4 Types of RSV Vaccines
    • 6.4.1. Nucleic Acid Based Vaccines
    • 6.4.2. Protein Based Vaccines
    • 6.4.3. Recombinant Vector Based Vaccines
    • 6.4.4. Live Attenuated Vaccines
  • 6.5. Benefits of RSV Vaccination
  • 6.6. Challenges Associated with Development of RSV Vaccines
  • 6.7. Future Perspectives

SECTION III: MARKET OVERVIEW

7. MARKET LANDSCAPE

  • 7.1. RSV Vaccines: Overall Market Landscape
    • 7.1.1. Analysis by Stage of Development
    • 7.1.2. Analysis by Route of Administration
    • 7.1.3. Analysis by Type of Vaccine
    • 7.1.4. Analysis by Type of Protein Targeted
    • 7.1.5. Analysis by Type of Immunization
    • 7.1.6. Analysis by Target Patient Population
    • 7.1.7. Analysis by Year of Establishment
    • 7.1.8. Analysis by Company Size
    • 7.1.9. Analysis by Location of Headquarters

8. PRODUCT COMPETITIVENESS ANALYSIS

  • 8.1. Assumptions and Key Parameters
  • 8.2. Methodology
  • 8.3. RSV Vaccines: Product Competitiveness Analysis
    • 8.3.1. RSV Vaccines Developed by Players Based in North America
    • 8.3.2. RSV Vaccines Developed by Players Based in Europe
    • 8.3.3. RSV Vaccines Developed by Players Based in Asia-Pacific and Rest of the World

SECTION IV: COMPANY PROFILES

9. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN NORTH AMERICA

  • 9.1. Icosavax (A Company of AstraZeneca)
    • 9.1.1. Company Details
    • 9.1.2. Product Portfolio
    • 9.1.3. Recent Developments and Future Outlook
  • 9.2. Moderna
    • 9.2.1. Company Details
    • 9.2.2. Product Portfolio
    • 9.2.3. Financial Details, FY 2021 onwards (USD Million)
    • 9.2.4. Recent Developments and Future Outlook
  • 9.3. Pfizer
    • 9.3.1. Company Details
    • 9.3.2. Product Portfolio
    • 9.3.3. Financial Details, FY 2021 onwards (USD Million)
    • 9.3.4. Recent Developments and Future Outlook

10. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN EUROPE

  • 10.1. GlaxoSmithKline
    • 10.1.1. Company Details
    • 10.1.2. Product Portfolio
    • 10.1.3. Financial Details, FY 2021 onwards (EUR Million)
    • 10.1.4. Recent Developments and Future Outlook
  • 10.2. Sanofi
    • 10.2.1. Company Details
    • 10.2.2. Product Portfolio
    • 10.2.3. Financial Details, FY 2021 onwards (EUR Million)
    • 10.2.4. Recent Developments and Future Outlook

11. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN ASIA-PACIFIC

  • 11.1. Beijing Advaccine Biotechnology
    • 11.1.1. Company Details
    • 11.1.2. Product Portfolio

SECTION V: MARKET TRENDS

12. CLINICAL TRIALS ANALYSIS

  • 12.1. Scope and Methodology
  • 12.2. RSV Vaccines: Clinical Trial Analysis
    • 12.2.1. Analysis by Trial Registration Year, Since 2015
    • 12.2.2. Analysis by Trial Status
    • 12.2.3. Analysis of Enrolled Patient Population by Trial Registration Year, Since 2015
    • 12.2.4. Analysis by Trial Registration Year and Trial Status, Since 2015
    • 12.2.5. Analysis by Trial Phase
    • 12.2.6. Analysis of Enrolled Patient Population by Trial Phase
    • 12.2.7. Analysis by Study Design
    • 12.2.8. Analysis by Type of Sponsor / Collaborator
    • 12.2.9. Analysis by Gender
    • 12.2.10. Analysis by Target Patient Population
    • 12.2.11. Leading Players: Analysis by Number of Registered Trials
    • 12.2.12. Analysis by Geography
    • 12.2.13. Analysis by Trial Status and Geography
    • 12.2.14. Analysis of Enrolled Patient Population by Trial Status and Geography

13. PATENT ANALYSIS

  • 13.1. Scope and Methodology
  • 13.2. RSV Vaccines: Patent Analysis
    • 13.2.1. Analysis by Patent Publication Year, Since 2020
    • 13.2.2. Analysis by Type of Patent
    • 13.2.3. Analysis by Type of Patent and Publication Year, Since 2020
    • 13.2.4. Analysis by Patent Application Year, Since 2008
    • 13.2.5. Analysis by Patent Age
    • 13.2.6. Analysis by Type of Applicant
    • 13.2.7. Analysis by Patent Jurisdiction
    • 13.2.8. Analysis by CPC Symbols
    • 13.2.9. Leading Industry Players: Analysis by Number of Patents
    • 13.2.10. Leading Non-Industry Players: Analysis by Number of Patents
    • 13.2.11. Leading Inventors: Analysis by Number of Patents
  • 13.3. Patent Benchmarking Analysis
    • 13.3.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
    • 13.3.2. Analysis of Leading Industry Players by Patent Characteristics (CPC Codes)
  • 13.4. Patent Valuation
  • 13.5. Leading Patents by Number of Citations

14. FDA APPROVAL STRATEGIES

  • 14.1. Chapter Overview
  • 14.2. Methodology
  • 14.3. Key Parameters
  • 14.4. General Reasons for Failure of Trials Focused on RSV vaccines
  • 14.5. Benchmarking Analysis: Distribution of Key Strategies by Vaccines

SECTION VI: MARKET OPPORTUNITY ANALYSIS

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Market Drivers
  • 15.2. Market Restraints
  • 15.3. Market Opportunities
  • 15.4. Market Challenges

16. GLOBAL RSV VACCINE MARKET

  • 16.1. Key Assumptions and Methodology
  • 16.2. Global RSV Vaccine Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 16.2.1. Multivariate Scenario Analysis
      • 16.2.1.1. Conservative Scenario
      • 16.2.1.2. Optimistic Scenario
  • 16.3. Key Market Segmentations

17. RSV VACCINE MARKET, BY TYPE OF VACCINE

  • 17.1. Key Assumptions and Methodology
  • 17.2. RSV Vaccine Market: Distribution by Type of Vaccine
    • 17.2.1. RSV Vaccine Market for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 17.2.2. RSV Vaccine Market for Live Attenuated Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 17.2.3. RSV Vaccine Market for mRNA Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 17.3. Data Triangulation and Validation

18. RSV VACCINE MARKET, BY ROUTE OF ADMINISTRATION

  • 18.1. Key Assumptions and Methodology
  • 18.2. RSV Vaccine Market: Distribution by Route of Administration
    • 18.2.1. RSV Vaccine Market for Intramuscular, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 18.2.2. RSV Vaccine Market for Other Routes, Historical Trends (Since2023) and Forecasted Estimates Till 2040) (USD Million)
  • 18.3. Data Triangulation and Validation

19. RSV VACCINE MARKET, BY TARGET PATIENT POPULATION

  • 19.1. Key Assumptions and Methodology
  • 19.2. RSV Vaccine Market: Distribution by Target Patient Population
    • 19.2.1. RSV Vaccine Market for Elderly Individuals, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 19.2.2. RSV Vaccine Market for Infants / Children, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 19.2.3. RSV Vaccine Market for Pregnant Individuals, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 19.3. Data Triangulation and Validation

20. RSV VACCINE MARKET, BY DISTRIBUTION CHANNEL

  • 20.1. Key Assumptions and Methodology
  • 20.2. RSV Vaccine Market: Distribution by Distribution Channel
    • 20.2.1. RSV Vaccine Market for Pharmacies and Drug Stores, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 20.2.2. RSV Vaccine Market for Government / Institutional Suppliers, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 20.2.3. RSV Vaccine Market for Others, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 20.3. Data Triangulation and Validation

21. RSV VACCINE MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Key Assumptions and Methodology
  • 21.2. RSV Vaccine Market: Distribution by Key Geographical Regions
    • 21.2.1. RSV Vaccine Market in North America, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 21.2.2. RSV Vaccine Market in Europe, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 21.3. Market Movement Analysis
  • 21.4. Penetration-Growth (P-G) Matrix
  • 21.5. Data Triangulation and Validation

22. MARKET CONCENTRATION ANALYSIS: DISTRIBUTION BY LEADING PLAYERS

  • 22.1. Key Assumptions and Methodology
  • 22.2. RSV Vaccine Market: Leading RSV Vaccines Developers
  • 22.3. Data Triangulation and Validation

SECTION VII: MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHICAL REGIONS**

23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

  • 23.1. RSV Vaccine Market in North America: Distribution by Type of Vaccine
    • 23.1.1. RSV Vaccine Market in North America for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.1.2. RSV Vaccine Market in North America for Live Attenuated Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.1.3. RSV Vaccine Market in North America for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 23.2. RSV Vaccine Market in North America: Distribution by Route of Administration
    • 23.2.1. RSV Vaccine Market in North America for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.2.2. RSV Vaccine Market in North America for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 23.3. RSV Vaccine Market in North America: Distribution by Target Patient Population
    • 23.3.1. RSV Vaccine Market in North America for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.3.2. RSV Vaccine Market in North America for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.3.3. RSV Vaccine Market in North America for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 23.4. RSV Vaccine Market in North America: Distribution by Distribution Channel
    • 23.4.1. RSV Vaccine Market in North America for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.4.2. RSV Vaccine Market in North America for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.4.3. RSV Vaccine Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24. MARKET OPPORTUNITY ANALYSIS: EUROPE

  • 24.1. RSV Vaccine Market in Europe: Distribution by Type of Vaccine
    • 24.1.1. RSV Vaccine Market in Europe for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.1.2. RSV Vaccine Market in Europe for Live Attenuated Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.1.3. RSV Vaccine Market in Europe for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 24.2. RSV Vaccine Market in Europe: Distribution by Route of Administration
    • 24.2.1. RSV Vaccine Market in Europe for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.2.2. RSV Vaccine Market in Europe for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 24.3. RSV Vaccine Market in Europe: Distribution by Target Patient Population
    • 24.3.1. RSV Vaccine Market in Europe for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.3.2. RSV Vaccine Market in Europe for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.3.3. RSV Vaccine Market in Europe for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 24.4. RSV Vaccine Market in Europe: Distribution by Distribution Channel
    • 24.4.1. RSV Vaccine Market in Europe for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.4.2. RSV Vaccine Market in Europe for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.4.3. RSV Vaccine Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • *Detailed information on Section VII is available in the Excel Data Packs shared along with the report**

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

25. CONCLUSION

26. EXECUTIVE INSIGHTS

SECTION IX: APPENDIX

27. TABULATED DATA

28. LIST OF COMPANIES AND ORGANIZATIONS